keyword
MENU ▼
Read by QxMD icon Read
search

allergoids

keyword
https://www.readbyqxmd.com/read/29997888/early-nonreactivity-in-the-conjunctival-provocation-test-predicts-beneficial-outcome-of-sublingual-immunotherapy
#1
Janina Köther, Alicia Mandl, Silke Allekotte, Anatoli Astvatsatourov, Janin Chwieralski, Jan-Patrick Liedtke, Ursula Pieper-Fürst, Esther Raskopf, Kija Shah-Hosseini, Ralph Mösges
Background: Clinical practice needs a common parameter that can provide an early, reliable estimation of the outcome of sublingual immunotherapy (SLIT) in an upcoming pollen season. We investigated whether the conjunctival provocation test (CPT) can predict the beneficial outcome of SLIT in patients with allergic rhinoconjunctivitis after 4 weeks of treatment. Methods: We conducted two separate prospective, randomized, double-blind, placebo-controlled, multicenter trials...
2018: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/29779247/randomized-controlled-trials-define-shape-of-dose-response-for-pollinex-quattro-birch-allergoid-immunotherapy
#2
M Worm, T Higenbottam, O Pfaar, R Mösges, W Aberer, K Gunawardena, D Wessiepe, D Lee, M F Kramer, M Skinner, B Lees, S Zielen
BACKGROUND: The Birch Allergoid, Tyrosine Adsorbate, Monophosphoryl Lipid A (POLLINEX® Quattro Plus 1.0 ml Birch 100%) is an effective, well-tolerated short course subcutaneous immunotherapy. We performed 2 phase II studies to determine its optimal cumulative dose. METHODS: The studies were conducted in Germany, Austria and Poland (EudraCT numbers: 2012-004336-28 PQBirch203 and 2015-000984-15 PQBirch204) using a wide range of cumulative doses. In both studies, subjects were administered 6 therapy injections weekly outside the pollen season...
May 19, 2018: Allergy
https://www.readbyqxmd.com/read/29732290/novel-strategies-in-immunotherapy-for-allergic-diseases
#3
REVIEW
Mohana Rajakulendran, Elizabeth Huiwen Tham, Jian Yi Soh, H P Van Bever
Conventional immunotherapy (IT) for optimal control of respiratory and food allergies has been fraught with concerns of efficacy, safety, and tolerability. The development of adjuvants to conventional IT has potentially increased the effectiveness and safety of allergen IT, which may translate into improved clinical outcomes and sustained unresponsiveness even after cessation of therapy. Novel strategies incorporating the successful use of adjuvants such as allergoids, immunostimulatory DNA sequences, monoclonal antibodies, carriers, recombinant proteins, and probiotics have now been described in clinical and murine studies...
April 2018: Asia Pacific Allergy
https://www.readbyqxmd.com/read/29675865/allergen-immunotherapy-in-people-dogs-cats-and-horses-differences-similarities-and-research-needs
#4
R S Mueller, E Jensen-Jarolim, F Roth-Walter, E Marti, J Janda, A A Seida, D DeBoer
In human patients with seasonal allergic rhinoconjunctivitis sensitized to grass pollen, the first successful allergen immunotherapy (AIT) was reported in 1911. Today, immunotherapy is an accepted treatment for allergic asthma, allergic rhinitis and hypersensitivities to insect venom. AIT is also used for atopic dermatitis and recently for food allergy. Subcutaneous, epicutaneous, intralymphatic, oral and sublingual protocols of AIT exist. In animals, most data are available in dogs where subcutaneous AIT is an accepted treatment for atopic dermatitis...
April 19, 2018: Allergy
https://www.readbyqxmd.com/read/29473530/allergoids-for-allergy-treatment
#5
Jeronimo Carnes, Maria T Gallego, Raquel Moya, Victor Iraola
Background Chemically modified allergen extracts, known as allergoids, are commonly used for treating allergic patients. In general terms, the concept of allergoids implies allergen extracts with a reduction of their allergenicity maintaining their immunogenicity. Different methods to obtain allergoids have been developed in the past years, opening attractive lines of research. Objective To review the different approaches to allergoid development as well as their characterization, mechanism of action and efficacy and safety issues...
February 21, 2018: Recent Patents on Inflammation & Allergy Drug Discovery
https://www.readbyqxmd.com/read/29450658/modified-allergens-for-immunotherapy
#6
REVIEW
Pattraporn Satitsuksanoa, Anna Głobińska, Kirstin Jansen, Willem van de Veen, Mübeccel Akdis
PURPOSE OF REVIEW: During the past few decades, modified allergens have been developed for use in allergen-specific immunotherapy (AIT) with the aim to improve efficacy and reduce adverse effects. This review aims to provide an overview of the different types of modified allergens, their mechanism of action and their potential for improving AIT. RECENT FINDINGS: In-depth research in the field of allergen modifications as well as the advance of recombinant DNA technology have paved the way for improved diagnosis and research on human allergic diseases...
February 16, 2018: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/29422821/twenty-years-observation-of-subcutaneous-pollen-allergoid-immunotherapy-efficacy-in-adults
#7
Andrzej Bożek, Izabella Krupa-Borek, Jerzy Jarzab
Introduction: It is valuable to determine the long-term efficacy of allergen-specific immunotherapy (SIT) and whether it can cure allergy. Aim: For this study, patients were prospectively observed for 20 years after completion of SIT to determine its effectiveness. Material and methods: A total of 1006 patients who underwent SIT for pollen allergy were observed for 20 years to assess the efficacy of SIT. The rhinitis symptom score (RSS) and asthma symptom score (ASS) were measured after SIT completion...
December 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29413339/current-insights-in-allergen-immunotherapy
#8
REVIEW
Giovanni Passalacqua, Diego Bagnasco, Matteo Ferrando, Enrico Heffler, Francesca Puggioni, Giorgio Walter Canonica
OBJECTIVE: Allergen-specific immunotherapy (AIT) in its subcutaneous and sublingual forms is currently a well-established and experimentally supported treatment for respiratory allergy and hymenoptera venom allergy. There have been advances in its use linked strictly to the advancement in the knowledge of the molecular mechanisms of allergy, the production of well-characterized extracts, and diagnostic techniques. The use of AIT in asthma and the application of new approaches are expanding...
February 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29342409/development-and-characterization-of-an-allergoid-of-cat-dander-for-immunotherapy
#9
J P Sola, Y Pedreño, A Cerezo, M Peñalver-Mellado
BACKGROUND: Allergy to cats is a frequent cause of sensitization to indoor allergens and currently there are few alternatives to specific immunotherapy with cat native extracts. The objective is to develop and characterize a new allergoid to increase the tools available for use in clinical practice. METHODS: The allergoid cat dander extract (ACD) was developed from a native cat dander extract (NCD) by modification with glutaraldehyde, and the optimal process control was determined by SDS-PAGE, DOT BLOT and determination of free amine groups...
January 13, 2018: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/29319882/oral-myeloid-cells-uptake-allergoids-coupled-to-mannan-driving-th1-treg-responses-upon-sublingual-delivery-in-mice
#10
I Soria, J López-Relaño, M Viñuela, J-I Tudela, A Angelina, C Benito-Villalvilla, C M Díez-Rivero, B Cases, A I Manzano, E Fernández-Caldas, M Casanovas, O Palomares, J L Subiza
BACKGROUND: Polymerized allergoids coupled to nonoxidized mannan (PM-allergoids) may represent novel vaccines targeting dendritic cells (DCs). PM-allergoids are better captured by DCs than native allergens and favor Th1/Treg cell responses upon subcutaneous injection. Herein we have studied in mice the in vivo immunogenicity of PM-allergoids administered sublingually in comparison with native allergens. METHODS: Three immunization protocols (4-8 weeks long) were used in Balb/c mice...
April 2018: Allergy
https://www.readbyqxmd.com/read/29150848/allergen-manufacturing-and-quality-aspects-for-allergen-immunotherapy-in-europe-and-the-united-states-an-analysis-from-the-eaaci-ait-guidelines-project
#11
REVIEW
A Bonertz, G Roberts, J E Slater, J Bridgewater, R L Rabin, M Hoefnagel, M Timon, C Pini, O Pfaar, A Sheikh, D Ryan, C Akdis, J Goldstein, L K Poulsen, R van Ree, C Rhyner, D Barber, O Palomares, R Pawankar, D Hamerlijnk, L Klimek, I Agache, E Angier, T Casale, M Fernandez-Rivas, S Halken, M Jutel, S Lau, G Pajno, G Sturm, E M Varga, R Gerth van Wijk, S Bonini, A Muraro, S Vieths
Adequate quality is essential for any medicinal product to be eligible for marketing. Quality includes verification of the identity, content and purity of a medicinal product in combination with a specified production process and its control. Allergen products derived from natural sources require particular considerations to ensure adequate quality. Here, we describe key aspects of the documentation on manufacturing and quality aspects for allergen immunotherapy products in the European Union and the United States...
April 2018: Allergy
https://www.readbyqxmd.com/read/29130797/dose-finding-study-of-carbamylated-monomeric-allergoid-tablets-in-grass-allergic-rhinoconjunctivitis-patients
#12
Ralph Mösges, Christina Rohdenburg, Andrea Eichel, Gregor Zadoyan, Elena-Manja Kasche, Kija Shah-Hosseini, Walter Lehmacher, Petra Schmalz, Enrico Compalati
AIM: To determine the optimal effective and safe dose of sublingual immunotherapy tablets containing carbamylated monomeric allergoids in patients with grass pollen-induced allergic rhinoconjunctivitis. METHODS: In this prospective, randomized, double-blind, active-controlled, multicenter, Phase II study, four different daily doses were applied preseasonally for 12 weeks. RESULTS: Of 158 randomized adults, 155 subjects (safety population) received 300 units of allergy (UA)/day (n = 36), 600 UA/day (n = 43), 1000 UA/day (n = 39), or 2000 UA/day (n = 37)...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29128092/quality-requirements-for-allergen-extracts-and-allergoids-for-allergen-immunotherapy
#13
REVIEW
J Zimmer, A Bonertz, S Vieths
All allergen products for allergen immunotherapy currently marketed in the European Union are pharmaceutical preparations derived from allergen-containing source materials like pollens, mites and moulds. Especially this natural origin results in particular demands for the regulatory requirements governing allergen products. Furthermore, the development of regulatory requirements is complicated by the so far missing universal link between certain quality parameters, in particular biological potency, on the one hand and clinical efficacy on the other hand...
November 8, 2017: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/28941667/advances-and-highlights-in-allergen-immunotherapy-on-the-way-to-sustained-clinical-and-immunologic-tolerance
#14
REVIEW
Margot Berings, Cagatay Karaaslan, Can Altunbulakli, Philippe Gevaert, Mübeccel Akdis, Claus Bachert, Cezmi A Akdis
Allergen immunotherapy (AIT) is an effective treatment strategy for allergic diseases and has been used for more than 100 years. In recent years, however, the expectations on concepts, conduct, statistical evaluation, and reporting have developed significantly. Products have undergone dose-response and confirmative studies in adults and children to provide evidence for the optimal dosage, safety, and efficacy of AIT vaccines using subcutaneous and sublingual delivery pathways in large patient cohorts, ensuring solid conclusions to be drawn from them for the advantage of patients and societies alike...
November 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28696503/dose-response-relationship-of-a-new-timothy-grass-pollen-allergoid-in-comparison-with-a-6-grass-pollen-allergoid
#15
O Pfaar, J M Hohlfeld, B Al-Kadah, B Hauswald, B Homey, N Hunzelmann, S Schliemann, P Velling, M Worm, L Klimek
BACKGROUND: Subcutaneous allergen immunotherapy with grass pollen allergoids has been proven to be effective and safe in the treatment of patients with allergic rhinoconjunctivitis. Based on the extensive cross-reactivity among Pooideae species, it has been suggested that grass pollen extracts could be prepared from a single species, rather than from a multiple species mixture. OBJECTIVE: To find the optimal dose of a Phleum pratense (P. pratense) allergoid preparation and compare its efficacy and safety to a 6-grass pollen allergoid preparation...
November 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28675499/ultra-short-course-booster-is-effective-in-recurrent-grass-pollen-induced-allergic-rhinoconjunctivitis
#16
O Pfaar, S Lang, U Pieper-Fürst, A Astvatsatourov, F Gerich, L Klimek, M F Kramer, Y Reydelet, K Shah-Hosseini, R Mösges
BACKGROUND: A relevant proportion of allergic rhinoconjunctivitis (ARC) patients experience recurrent symptoms after successfully completing allergen immunotherapy (AIT). This prospective, controlled, noninterventional study used internationally standardized instruments to determine the clinical effects of a preseasonal, ultra-short-course booster AIT on clinical outcome parameters. METHODS: This two-arm study included patients aged ≥12 years with recurrent grass pollen-induced seasonal AR who had completed a successful course of any grass pollen AIT at least 5 years before enrolment...
January 2018: Allergy
https://www.readbyqxmd.com/read/28532268/allergen-immunotherapy-in-allergic-rhinitis-current-use-and-future-trends
#17
REVIEW
Ludger Klimek, Oliver Pfaar, Jean Bousquet, Gabriela Senti, Thomas Kündig
Type-1 allergies are among the most chronic common diseases of humans. Allergen immunotherapy (AIT) is the only causative and disease-modifying treatment option besides allergen avoidance. Severe systemic adverse allergic reactions may be induced by every AIT treatment. Different approaches have been used to provide safer AIT preparations to lower or even totally overcome this risk. Areas covered: A structured literature recherche in Medline and Pubmed under inclusion of national and international guidelines and Cochrane meta-analyses has been performed aiming at reviewing clinical use of such approaches in AIT...
September 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28451054/molecular-fingerprinting-of-complex-grass-allergoids-size-assessments-reveal-new-insights-in-epitope-repertoires-and-functional-capacities
#18
S Starchenka, A J Bell, J Mwange, M A Skinner, M D Heath
BACKGROUND: Subcutaneous allergen immunotherapy (SCIT) is a well-documented treatment for allergic disease which involves injections of native allergen or modified (allergoid) extracts. The use of allergoid vaccines is a growing sector of the allergy immunotherapy market, associated with shorter-course therapy. The aim of this study was the structural and immunological characterisation of group 1 (Lol p 1) IgG-binding epitopes within a complex mix grass allergoid formulation containing rye grass...
2017: World Allergy Organization Journal
https://www.readbyqxmd.com/read/28380494/accelerated-up-dosing-of-subcutaneous-immunotherapy-with-a-registered-allergoid-birch-pollen-preparation
#19
RANDOMIZED CONTROLLED TRIAL
Krzysztof Buczyłko, Jan F van der Werf, Diderik Boot, Ronald van Ree
BACKGROUND: Early pollen flight and new allergens prolonging the pollen season means that the time for up-dosing of allergen-specific subcutaneous immunotherapy (SCIT) outside the pollen season becomes shorter. Hence, for patients who wish or need to be up-dosed faster, an accelerated induction regimen would provide a useful treatment option. METHODS: An accelerated up-dosing regimen (0.1-0.3-0.5 mL at weekly intervals) was compared to conventional up-dosing (0...
2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28235411/in-vitro-evidence-of-efficacy-and-safety-of-a-polymerized-cat-dander-extract-for-allergen-immunotherapy
#20
María Morales, Mayte Gallego, Victor Iraola, Marta Taulés, Eliandre de Oliveira, Raquel Moya, Jerónimo Carnés
BACKGROUND: Allergy to cat epithelia is highly prevalent, being the major recommendation for allergy sufferers its avoidance. However, this is not always feasible. Allergen specific immunotherapy is therefore recommended for these patients. The use of polymerized allergen extracts, allergoids, would allow to achieve the high allergen doses suggested to be effective while maintaining safety. RESULTS: Cat native extract and its depigmented allergoid were manufactured and biochemically and immunochemically characterized...
February 24, 2017: BMC Immunology
keyword
keyword
109765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"